177 related articles for article (PubMed ID: 16457694)
1. Preclinical evaluation of transcriptional targeting strategies for carcinoma of the breast in a tissue slice model system.
Stoff-Khalili MA; Stoff A; Rivera AA; Banerjee NS; Everts M; Young S; Siegal GP; Richter DF; Wang M; Dall P; Mathis JM; Zhu ZB; Curiel DT
Breast Cancer Res; 2005; 7(6):R1141-52. PubMed ID: 16457694
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of tumor-specific promoter activities in melanoma.
Lu B; Makhija SK; Nettelbeck DM; Rivera AA; Wang M; Komarova S; Zhou F; Yamamoto M; Haisma HJ; Alvarez RD; Curiel DT; Zhu ZB
Gene Ther; 2005 Feb; 12(4):330-8. PubMed ID: 15696177
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of tissue-specific promoters in carcinomas of the cervix uteri.
Rein DT; Breidenbach M; Nettelbeck DM; Kawakami Y; Siegal GP; Huh WK; Wang M; Hemminki A; Bauerschmitz GJ; Yamamoto M; Adachi Y; Takayama K; Dall P; Curiel DT
J Gene Med; 2004 Nov; 6(11):1281-9. PubMed ID: 15368588
[TBL] [Abstract][Full Text] [Related]
4. Transcriptional targeting of adenoviral vector through the CXCR4 tumor-specific promoter.
Zhu ZB; Makhija SK; Lu B; Wang M; Kaliberova L; Liu B; Rivera AA; Nettelbeck DM; Mahasreshti PJ; Leath CA; Yamamoto M; Alvarez RD; Curiel DT
Gene Ther; 2004 Apr; 11(7):645-8. PubMed ID: 15029227
[TBL] [Abstract][Full Text] [Related]
5. The secretory leukoprotease inhibitor (SLPI) promoter for ovarian cancer gene therapy.
Barker SD; Coolidge CJ; Kanerva A; Hakkarainen T; Yamamoto M; Liu B; Rivera AA; Bhoola SM; Barnes MN; Alvarez RD; Curiel DT; Hemminki A
J Gene Med; 2003 Apr; 5(4):300-10. PubMed ID: 12692864
[TBL] [Abstract][Full Text] [Related]
6. Combining high selectivity of replication via CXCR4 promoter with fiber chimerism for effective adenoviral oncolysis in breast cancer.
Stoff-Khalili MA; Rivera AA; Stoff A; Michael Mathis J; Rocconi RP; Matthews QL; Numnum MT; Herrmann I; Dall P; Eckhoff DE; Douglas JT; Siegal GP; Zhu ZB; Curiel DT
Int J Cancer; 2007 Feb; 120(4):935-41. PubMed ID: 17131341
[TBL] [Abstract][Full Text] [Related]
7. Adenovirus-mediated transcriptional targeting of colorectal cancer and effects on treatment-resistant hypoxic cells.
Rajendran S; O'Sullivan GC; O'Hanlon D; Tangney M
Clin Colorectal Cancer; 2013 Sep; 12(3):152-162.e1. PubMed ID: 23313233
[TBL] [Abstract][Full Text] [Related]
8. Cancer-specific targeting of a conditionally replicative adenovirus using mRNA translational control.
Stoff-Khalili MA; Rivera AA; Nedeljkovic-Kurepa A; DeBenedetti A; Li XL; Odaka Y; Podduturi J; Sibley DA; Siegal GP; Stoff A; Young S; Zhu ZB; Curiel DT; Mathis JM
Breast Cancer Res Treat; 2008 Mar; 108(1):43-55. PubMed ID: 17508279
[TBL] [Abstract][Full Text] [Related]
9. Comparative evaluation of survivin, midkine and CXCR4 promoters for transcriptional targeting of glioma gene therapy.
Ulasov IV; Rivera AA; Sonabend AM; Rivera LB; Wang M; Zhu ZB; Lesniak MS
Cancer Biol Ther; 2007 May; 6(5):679-85. PubMed ID: 17404502
[TBL] [Abstract][Full Text] [Related]
10. A new targeting approach for breast cancer gene therapy using the heparanase promoter.
Breidenbach M; Rein DT; Schöndorf T; Khan KN; Herrmann I; Schmidt T; Reynolds PN; Vlodavsky I; Haviv YS; Curiel DT
Cancer Lett; 2006 Aug; 240(1):114-22. PubMed ID: 16271435
[TBL] [Abstract][Full Text] [Related]
11. Transcriptional targeting of tumors with a novel tumor-specific survivin promoter.
Zhu ZB; Makhija SK; Lu B; Wang M; Kaliberova L; Liu B; Rivera AA; Nettelbeck DM; Mahasreshti PJ; Leath CA; Barker S; Yamaoto M; Li F; Alvarez RD; Curiel DT
Cancer Gene Ther; 2004 Apr; 11(4):256-62. PubMed ID: 15017380
[TBL] [Abstract][Full Text] [Related]
12. Tumor-specific adenovirus-mediated PUMA gene transfer using the survivin promoter enhances radiosensitivity of breast cancer cells in vitro and in vivo.
Wang R; Wang X; Li B; Lin F; Dong K; Gao P; Zhang HZ
Breast Cancer Res Treat; 2009 Sep; 117(1):45-54. PubMed ID: 18791823
[TBL] [Abstract][Full Text] [Related]
13. Transcriptional targeting in renal cancer cell lines via the human CXCR4 promoter.
Haviv YS; van Houdt WJ; Lu B; Curiel DT; Zhu ZB
Mol Cancer Ther; 2004 Jun; 3(6):687-91. PubMed ID: 15210854
[TBL] [Abstract][Full Text] [Related]
14. Gene transfer to carcinoma of the breast with fiber-modified adenoviral vectors in a tissue slice model system.
Stoff-Khalili MA; Stoff A; Rivera AA; Mathis JM; Everts M; Wang M; Kawakami Y; Waehler R; Mathews QL; Yamamoto M; Rocconi RP; Siegal GP; Richter DF; Dall P; Zhu ZB; Curiel DT
Cancer Biol Ther; 2005 Nov; 4(11):1203-10. PubMed ID: 16177567
[TBL] [Abstract][Full Text] [Related]
15. A fiber-modified, secretory leukoprotease inhibitor promoter-based conditionally replicating adenovirus for treatment of ovarian cancer.
Rein DT; Breidenbach M; Kirby TO; Han T; Siegal GP; Bauerschmitz GJ; Wang M; Nettelbeck DM; Tsuruta Y; Yamamoto M; Dall P; Hemminki A; Curiel DT
Clin Cancer Res; 2005 Feb; 11(3):1327-35. PubMed ID: 15709205
[TBL] [Abstract][Full Text] [Related]
16. The carcinoma-specific epithelial glycoprotein-2 promoter controls efficient and selective gene expression in an adenoviral context.
Gommans WM; van Eert SJ; McLaughlin PM; Harmsen MC; Yamamoto M; Curiel DT; Haisma HJ; Rots MG
Cancer Gene Ther; 2006 Feb; 13(2):150-8. PubMed ID: 16096650
[TBL] [Abstract][Full Text] [Related]
17. Combined transcriptional and transductional targeting improves the specificity and efficacy of adenoviral gene delivery to ovarian carcinoma.
Barker SD; Dmitriev IP; Nettelbeck DM; Liu B; Rivera AA; Alvarez RD; Curiel DT; Hemminki A
Gene Ther; 2003 Jul; 10(14):1198-204. PubMed ID: 12833129
[TBL] [Abstract][Full Text] [Related]
18. The human survivin promoter: a novel transcriptional targeting strategy for treatment of glioma.
Van Houdt WJ; Haviv YS; Lu B; Wang M; Rivera AA; Ulasov IV; Lamfers ML; Rein D; Lesniak MS; Siegal GP; Dirven CM; Curiel DT; Zhu ZB
J Neurosurg; 2006 Apr; 104(4):583-92. PubMed ID: 16619663
[TBL] [Abstract][Full Text] [Related]
19. A novel, conditionally replicative adenovirus for the treatment of breast cancer that allows controlled replication of E1a-deleted adenoviral vectors.
Hernandez-Alcoceba R; Pihalja M; Wicha MS; Clarke MF
Hum Gene Ther; 2000 Sep; 11(14):2009-24. PubMed ID: 11020800
[TBL] [Abstract][Full Text] [Related]
20. Incorporating the survivin promoter in an infectivity enhanced CRAd-analysis of oncolysis and anti-tumor effects in vitro and in vivo.
Zhu ZB; Makhija SK; Lu B; Wang M; Rivera AA; Kim-Park S; Ulasov IV; Zhou F; Alvarez RD; Siegal GP; Curiel DT
Int J Oncol; 2005 Jul; 27(1):237-46. PubMed ID: 15942665
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
